NCT00104286终止1 期
An Open-Label, Single-Arm, Phase I Study of Troxatyl™ (Troxacitabine) Administered by Continuous Infusion in Subjects With an Advanced Solid Malignancy
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- To determine the recommended infusion schedule for the investigational new drug administered as a continuous infusion, and to define the safety tolerance and dose limiting toxicities.
研究概览
简要总结
This is a phase I, single-arm, open-label, single-center study to establish the recommended infusion schedule for Troxatyl™ administered as a continuous infusion for 2-5 days to subjects with solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of advanced solid malignancy refractory to prior therapy and unlikely to benefit from known therapies (e.g., chemotherapy, radiation therapy, and surgery).
- •Diagnosis confirmed histologically or cytologically.
- •Subjects may have received prior cancer therapy (including surgery, radiotherapy, chemotherapy, and hormonal therapy), but must have completed all therapies at least 30 days prior to study drug administration (42 days for nitrosourea or mitomycin).
- •Subjects must have recovered from the toxic effects associated with prior treatment.
- •Subjects must have an Eastern Cooperative Oncology Group performance status of ≤ 2 and an estimated life expectancy of at least 12 weeks.
- •Subjects must have adequate organ and immune function as indicated by standard laboratory tests.
- •The subject must understand, be able, willing, and likely to fully comply with study procedures, including scheduled follow-up, and restrictions.
- •The subject must give written, personally signed and dated, informed consent to participate in the study before implementing any study related procedures.
排除标准
- •Previously documented brain metastases.
- •Active and uncontrolled infection.
- •Subjects with uncontrolled medical problems, unrelated to the malignancy, or of sufficient severity that in the opinion of the investigator, impair their ability to give informed consent or unacceptably reduce the safety of the proposed treatment.
- •Neurological or psychiatric disorders that would interfere with consent or study follow-up.
- •Prior treatment with more than 6 courses of alkylating agent-containing chemotherapy (except low-dose cisplatin) or more than 4 courses of carboplatin, radiation therapy to > 25% of hematopoietic reserves or two or more courses of mitomycin C or nitrosourea.
- •Known or suspected intolerance or hypersensitivity to the study materials [or closely related compounds] or any of their stated ingredients.
- •History of alcohol or other substance abuse within the last year.
- •Use of another investigational agent or participation in a clinical trial within 30 days prior to enrollment.
- •Female subjects who are pregnant or lactating, including females with a positive pregnancy test at screening must be excluded.
- •Subjects that have previously been enrolled into this study and subsequently withdrawn must also be excluded.
结局指标
主要结局
To determine the recommended infusion schedule for the investigational new drug administered as a continuous infusion, and to define the safety tolerance and dose limiting toxicities.
次要结局
- Pharmacokinetic/pharmacodynamic profile, preliminary evidence of the anti-tumor activity.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor)Gout ArthritisNCT06277752Innovent Biologics (Suzhou) Co. Ltd.30
已完成
1 期
Drug Drug Interaction Study Of Crizotinib With Esomeprazole.HealthyNCT01549574Pfizer16
已完成
1 期
Japanese Bridging Study of Ivosidenib (AG-120) in Healthy SubjectsHealthyNCT03071770Agios Pharmaceuticals, Inc.60
已完成
1 期
A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic FunctionHepatic ImpairmentNCT01631097AVEO Pharmaceuticals, Inc.44
招募中
1 期
NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid TumorPancreatic CancerSolid TumorGastric CancerNCT06134960Peking University12